Thiopental sodium


Generic Medicine Info
Contraindications
Acute asthma, respiratory obstruction, severe respiratory disease, inability to maintain an adequate airway during procedure; severe shock, constrictive pericarditis, porphyria, myotonic dystrophy, complete absence of suitable veins, inflammatory conditions of mouth, jaw, and neck.
Special Precautions
Patient with other respiratory diseases, asthma, severe anaemia, burns, cachexia, CV disease, hypertension, endocrine insufficiency (e.g. Addison's disease, thyrotoxicosis, myxoedema, diabetes), haemodynamic instability (e.g. hypotension, hypovolaemia, dehydration, severe haemorrhage, shock), hyperkalaemia, toxaemia, myasthenia gravis; history of habituation or addiction to alcohol or drug abuse; increased intracranial pressure or blood urea. Debilitated and excessively premedicated patients. Patients taking metoclopramide, droperidol. Renal and hepatic impairment. Children and elderly. Pregnancy and lactation. Patient Counselling This drug may cause prolonged vertigo, disorientation or sedation, if affected, do not drive or operate machinery. Monitoring Parameters Monitor heart rate, respiratory rate and blood pressure. A test dose to evaluate patient's tolerance or unusual sensitivity to thiopental sodium is recommended.
Adverse Reactions
Significant: CNS depression, extravasation (e.g. venospasm, irritation, extensive necrosis, sloughing), hypotension, respiratory depression, reduction in cardiac output; risk in precipitating acute circulatory failure (in patients with CV disease, particularly constrictive pericarditis); severe or refractory hypokalaemia (when used for raised intracranial pressure); risk for haemolysis (concentrations <2%). Cardiac disorders: Arrhythmia, myocardial depression. Gastrointestinal disorders: Hiccups. General disorders and administration site conditions: Shivering. Nervous system disorders: Somnolence, delayed wakening. Respiratory, thoracic and mediastinal disorders: Bronchospasm, laryngospasm, coughing, snoring.
Drug Interactions
Concurrent use with metoclopramide, droperidol, sulfonamides (e.g. sulfisoxazole) may enhance the therapeutic effect of thiopental sodium. May produce synergistic effects on CNS with other CNS depressants (e.g. those used for premedication). May potentiate hypotensive effect, CNS excitatory effects and sedative effects with antipsychotics (e.g. phenothiazine). May potentiate respiratory depressant effect and decrease antinociceptive effect with opioid analgesics. May reduce the analgesic effect of pethidine. May enhance toxicity with ketamine. Diminished therapeutic effect with aminophylline. Potentiated anaesthetic effect with midazolam, probenecid, aspirin. May enhance CNS depressant effect with Mg sulfate. May enhance the hypotensive effect of diazoxide, diuretics, nitrates, antihypertensives (e.g. methyldopa, moxonidine, hydralazine, minoxidil, Ca antagonists, ACE inhibitors, α and β-blockers), adrenergic neurone blockers. May diminish the therapeutic efficacy of estrogen.
CIMS Class
Anaesthetics- local & general
Disclaimer: This information is independently developed by CIMS based on thiopental sodium from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in